Enanta Pharmaceuticals Inc. ENTA
Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026
Enanta Pharmaceuticals Inc. (ENTA) is a healthcare company listed in the US with a market value of about $320M. In the twelve months to June 30, 2026 it had revenue of $65M and net income of -$63M, a net margin of -96.9%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -12% a year, a 5-year average ROIC of -47%.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2013. Revenue went from $48M in 2014 to $65M in 2025, growth of about 2.9% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 4% over three years (dilution for shareholders). It spends 163% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65M | $65M | $68M | $79M | $86M | $97M | $122M | $205M | $207M | $103M | $88M |
| Net income | -$63M | -$82M | -$116M | -$134M | -$122M | -$79M | -$36M | $46M | $72M | $18M | $22M |
| Free cash flow | -$37M | -$32M | -$97M | -$112M | -$87M | -$71M | $6M | $66M | $26M | $50M | $31M |
| EPS (diluted) | $-2.42 | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 | $-1.81 | $2210.00 | $3480.00 | $910.00 | $1130.00 |
| Net margin | -96.9% | -125.4% | -171.6% | -168.9% | -141.3% | -81.4% | -29.5% | 22.6% | 34.8% | 17.2% | 24.6% |
| ROIC | — | -68.2% | -65.1% | -44.6% | -35.6% | -19.9% | -7.1% | 6.2% | 17.3% | 5.4% | 7.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $21.83, 99% above the current price; targets range from $19.00 to $32.00; the consensus rating is “none”; expected EPS is $-2.29 for the fiscal year ending September 30, 2026.
Frequently asked questions
Does Enanta Pharmaceuticals pay a dividend?
Not currently.
Is Enanta Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Enanta Pharmaceuticals scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.